SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Performance-Based Risk-Sharing Arrangements: An Updated International Review
3 references·2 citing·15 second hop
Performance-Based Risk-Sharing Arrangements: An Updated International Review (2017)Performance-Based Risk-Sharing Arrangemen…Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force (2013)Performance-Based Risk-Sharin…Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions (2012)Coverage with Evidence Develo…Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Linking payment to health out…Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Potential approaches for the …Performance-based managed entry agreements for new medicines in OECD countries and EU member states (2019)Performance-based managed ent…The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries (2013)Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods (2016)Measuring and Valuing Health Benefits for Economic Evaluation (2016)The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal (2017)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report (2005)How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries (2017)Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force (2020)Managed entry agreements for pharmaceuticals: the European experience (2013)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden (2014)ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe (2016)
this work references cited by second hop

References

  • 2013Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force319 cited
  • 2010Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers287 cited
  • 2012Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions144 cited

Cited by

  • 2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications75 cited
  • 2019Performance-based managed entry agreements for new medicines in OECD countries and EU member states65 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work